SuperworthSensus Healthcare SRTS
- Market cap
- $48.6M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 2.8×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $17.5M
- −53% on a year ago
- Net margin
- −88.5%
- Free cash flow yield
- −14.4%
Sensus Healthcare trades at 2.8× sales. Its trailing earnings are negative, so it has no PE. Revenue was $17.5M over the last twelve months, down 53% on a year earlier with a −88% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.9M−57% | $12.6M−4% | $10.7M+212% | $9.2M+104% | $8.8M+127% | $13.1M+4% | $8.3M−22% | $7.3M−21% | $6.9M−22% | $4.9M−62% | $3.4M−59% | $2.3M−69% | |
| Cost of revenue | $1.9M−39% | $4.7M−0% | $4M+123% | $3.8M+100% | $3.6M+89% | $6M+26% | $4M−0% | $4.4M+16% | $4.2M+16% | $3M−49% | $2.4M−40% | $1.5M−66% |
| Gross profit | $2M−66% | $7.8M−6% | $6.7M+311% | $5.4M+107% | $5.2M+163% | $7.1M−9% | $4.4M−35% | $2.9M−47% | $2.7M−48% | $1.9M−73% | $991K−77% | $769K−74% |
| R&D | $1.1M+45% | $677K−42% | $926K−16% | $866K+5% | $863K−20% | $1.6M+131% | $2.6M+181% | $1.5M+70% | $1.8M+111% | $1.9M+21% | $1.6M−39% | $1.1M−25% |
| SG&A | $2.8M−6% | $1.6M−48% | $1.6M−54% | $1.6M−46% | $1.6M−44% | $2.4M+53% | $2.2M+40% | $2M+26% | $1.9M+22% | $1.8M−27% | $2M−8% | $1.8M−10% |
| −$1.9M | $5.6M+34% | $2.9M | $2M | $1.5M | $1.7M−69% | −$2.6M | −$1.9M | −$2.6M | −$3.1M | −$4.4M+65% | −$3.2M+64% | |
| Interest expense | n/a | n/a | −$214K−12% | −$209K | n/a | n/a | −$184K−14% | −$183K−12% | n/a | n/a | n/a | n/a |
| Pre-tax income | −$1.6M | $5.8M+32% | $3.1M | $2.2M | $1.8M | $2M−66% | −$2.5M | −$1.8M | −$2.4M | −$3M | −$4.2M+72% | −$3.1M+74% |
| −$125K | $1.6M+1% | $827K | $579K | $559K | $410K−74% | $110K−87% | −$723K | −$1.5M | $174K−58% | −$1.6M | $5.7M | |
| Net income | −$1.5M | $4.2M+49% | $2.3M | $1.6M | $1.2M | $1.5M−63% | −$2.6M | −$1M | −$943K | −$3.2M | −$2.6M+2% | −$8.7M+744% |
| −$0.09 | $0.26+53% | $0.14 | $0.10 | $0.07 | $0.09−65% | −$0.16 | −$0.06 | −$0.06 | −$0.19 | −$0.16+0% | −$0.53+783% | |
| 16.3M−2% | 16.3M−1% | 16.3M+0% | 16.3M+1% | 16.3M+1% | 16.4M+1% | 16.3M+0% | 16.3M−0% | 16.3M−0% | 16.3M−1% | 16.5M+1% | 16.5M+1% |
Revenue: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
R&D: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
SG&A: Q1 FY15: 6 months less the 3 months printed beside them.
Operating income: Q1 FY15: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY15: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
Income tax: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
Net income: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
EPS, diluted: 13 periods, Q1 FY15 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY15: share-days: the 6-month average less the second quarter's. 7 periods, Q4 FY15 to Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY17 and Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY21 and Q4 FY23: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Sensus Healthcare's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| SRTSSensus Healthcare | $48.6M | n/m | 13.4× | 2.8× | −53% | −88.5% | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| EMBCEmbecta | $380.2M | 4.6× | 11.7× | 0.4× | −8% | 8.6% | |
| Peer median | $199.3M | 15.1× | 16.6× | 1.9× | +5% | 8.4% |
More on Sensus Healthcare
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .